Shanghai Himed Pharmaceutical

Shanghai Himed Pharmaceutical is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of innovative small molecule therapeutics. The company primarily focuses on oncology-supportive care and metabolic disorders, with a strategic emphasis on bringing globally validated mechanisms to the Chinese market. Its lead candidate, Anamorelin (HM01), is a selective ghrelin receptor agonist currently in Phase 3 development for cancer cachexia and anorexia. Himed also maintains an internal pipeline of metabolic drug candidates, including oral GLP-1 receptor agonists. The company leverages its location in the Zhangjiang Hi-Tech Park to foster collaborations and advance its clinical programs toward commercialization.